Therapy
Blinatumomab
Anti-CD3 × anti-CD19 BiTE (bispecific T cell engager, 55kDa tandem scFv): one arm grabs CD3 on any T cell, other arm grabs CD19 on B cell/tumour → forced T cell-tumour cell contact → CTL-mediated killing WITHOUT requiring MHC-I, antigen presentation, or prior T cell sensitisation.
Also called: Blincyto, BiTE, anti-CD3×CD19
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 5 and is affected by 1 concepts — mostly 2 receptor, 2 disease, 2 trial.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
B-ALL CR rate ~40% in heavily pre-treated; DLBCL (3rd-line+): ORR 43%; Step-up dosing protocol (9μg → 28μg over first 2 weeks) to prevent severe CRS.
Its connections at a glance
Each dot is a concept directly linked to Blinatumomab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I017 · concept status: established. Select any connection above to inspect evidence for that specific link.